Latest news with #Patent
Yahoo
12-05-2025
- Business
- Yahoo
AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
The Federal Circuit rejects Bruker Cellular's invalidity challenge to AbCellera's patent for microfluidic devices and their use in culturing cells VANCOUVER, British Columbia, May 12, 2025--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that the United States Court of Appeals for the Federal Circuit (CAFC) has by a Rule 36 Order affirmed judgment of validity of its U.S. Patent No. 10,087,408 ("the '408 Patent"). AbCellera's '408 Patent is directed to microfluidic devices and using such devices to culture and selectively recover cells. Previously Berkeley Lights Inc., now Bruker Cellular Analysis, Inc. (Bruker), a subsidiary of Bruker Corporation, challenged the claims of the '408 Patent alleging invalidity based on anticipation and obviousness over the prior art. The U.S. Patent Trial and Appeal Board (PTAB) rejected all of Bruker's arguments and now the CAFC has confirmed that all claims of AbCellera's '408 Patent are valid. AbCellera's '408 Patent is part of a multi-patent infringement litigation between AbCellera and Bruker pending in the U.S. District Court for the Northern District of California. "AbCellera welcomes the Federal Circuit's Rule 36 Order confirming the validity and strength of its microfluidic cell culture system patent claims," said Tryn Stimart, JD, Chief Legal and Compliance Officer of AbCellera. "AbCellera will continue to defend its intellectual property portfolio, and we look forward to proving this infringement case against Bruker pending before the District Court." About AbCellera Biologics Inc. AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit AbCellera Forward-Looking Statements This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. View source version on Contacts Inquiries Media: Tiffany Chiu; media@ +1(236)521-6774 Business Development: Murray McCutcheon, Ph.D.; partnering@ +1(604)559-9005 Investor Relations: Peter Ahn; ir@ +1(778)729-9116
Business Wire
12-05-2025
- Business
- Business Wire
AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that the United States Court of Appeals for the Federal Circuit (CAFC) has by a Rule 36 Order affirmed judgment of validity of its U.S. Patent No. 10,087,408 ('the '408 Patent'). AbCellera's '408 Patent is directed to microfluidic devices and using such devices to culture and selectively recover cells. Previously Berkeley Lights Inc., now Bruker Cellular Analysis, Inc. (Bruker), a subsidiary of Bruker Corporation, challenged the claims of the '408 Patent alleging invalidity based on anticipation and obviousness over the prior art. The U.S. Patent Trial and Appeal Board (PTAB) rejected all of Bruker's arguments and now the CAFC has confirmed that all claims of AbCellera's '408 Patent are valid. AbCellera's '408 Patent is part of a multi-patent infringement litigation between AbCellera and Bruker pending in the U.S. District Court for the Northern District of California. 'AbCellera welcomes the Federal Circuit's Rule 36 Order confirming the validity and strength of its microfluidic cell culture system patent claims,' said Tryn Stimart, JD, Chief Legal and Compliance Officer of AbCellera. 'AbCellera will continue to defend its intellectual property portfolio, and we look forward to proving this infringement case against Bruker pending before the District Court.' About AbCellera Biologics Inc. AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit AbCellera Forward-Looking Statements This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors are described under 'Risk Factors,' 'Management's Discussion and Analysis of Financial Condition and Results of Operations,' and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
Yahoo
12-05-2025
- Business
- Yahoo
AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
The Federal Circuit rejects Bruker Cellular's invalidity challenge to AbCellera's patent for microfluidic devices and their use in culturing cells VANCOUVER, British Columbia, May 12, 2025--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that the United States Court of Appeals for the Federal Circuit (CAFC) has by a Rule 36 Order affirmed judgment of validity of its U.S. Patent No. 10,087,408 ("the '408 Patent"). AbCellera's '408 Patent is directed to microfluidic devices and using such devices to culture and selectively recover cells. Previously Berkeley Lights Inc., now Bruker Cellular Analysis, Inc. (Bruker), a subsidiary of Bruker Corporation, challenged the claims of the '408 Patent alleging invalidity based on anticipation and obviousness over the prior art. The U.S. Patent Trial and Appeal Board (PTAB) rejected all of Bruker's arguments and now the CAFC has confirmed that all claims of AbCellera's '408 Patent are valid. AbCellera's '408 Patent is part of a multi-patent infringement litigation between AbCellera and Bruker pending in the U.S. District Court for the Northern District of California. "AbCellera welcomes the Federal Circuit's Rule 36 Order confirming the validity and strength of its microfluidic cell culture system patent claims," said Tryn Stimart, JD, Chief Legal and Compliance Officer of AbCellera. "AbCellera will continue to defend its intellectual property portfolio, and we look forward to proving this infringement case against Bruker pending before the District Court." About AbCellera Biologics Inc. AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit AbCellera Forward-Looking Statements This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. View source version on Contacts Inquiries Media: Tiffany Chiu; media@ +1(236)521-6774 Business Development: Murray McCutcheon, Ph.D.; partnering@ +1(604)559-9005 Investor Relations: Peter Ahn; ir@ +1(778)729-9116 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Telegraph
11-03-2025
- Business
- Telegraph
What is a Lucky 15 and how does it work?
A Lucky 15 is a multiple bet comprising four selections in 15 combinations of singles, doubles, trebles and an accumulator. This article explains in easy-to-understand terms how a Lucky 15 works and why it is ideal for Cheltenham, where there are seven top-class races on each of the four days of the Cheltenham Festival. Lucky 15s – the basics Lucky 15s are most commonly used for horse racing bets but can also be placed on other sports. A Lucky 15 consists of 15 bets of equal value made on four selections in separate events. It comprises four singles, six doubles, four trebles and a fourfold accumulator, and you only need one selection to win to ensure a return. However, the more selections that win, the higher your return will be. Lucky 15 permutations A Lucky 15 covers your four selections (called A, B, C and D here) in the following ways: Lucky 15s – advantages and disadvantages A Lucky 15 works well when you have four selections in which you have a good degree of confidence. One winner out of four guarantees some return but that number rises to three winning permutations for two winners, seven for three winners and 15 if all four come in. On the downside, each of the 15 bets must have the same unit stake, so you can't allocate a greater stake to, say, those bets involving any of your selections you think are stronger than the others. But you can work around this by placing the 15 bets individually and allocating different stakes to some. Take a look at the best betting offers from the UK's most respected betting sites Each-way Lucky 15 betting With an each-way Lucky 15, all the bets are each-way bets so there are 30 in total, making the total stake of an each-way Lucky 15 double that of a regular one. The main advantage of an each-way Lucky 15 is that you earn a return for each selection that places. Therefore, it makes sense to have selections in which the each-way place payout will be more than your original stake. So if a bookmaker is paying ⅕ of the odds for a place, back selections at 5/1 or greater, and if they are paying ¼ for a place, ensure the price is 4/1 or greater. Lucky 15 variations The most common similar multiple bet to a Lucky 15 is a Yankee, which consists of four selections as well but has only 11 permutations: the six doubles, four trebles and one accumulator. A Yankee saves on your stake money but a minimum of two selections must win to ensure a return. A Patent removes one more selection from the equation, so there are three singles, three doubles and a treble and, again, only one winner is needed to guarantee a return. If the Patent and Yankee can be considered smaller siblings of the Lucky 15 family, there are bigger (but more expensive) relatives too. They include: Lucky 31: Five selections (five singles, 10 doubles, 10 trebles, 5 fourfolds and one fivefold) Lucky 63: Six selections (six singles, 15 doubles, 20 trebles, 15 fourfolds, six fivefolds, one sixfold) Super Heinz (120 bets): Seven selections (21 doubles, 35 trebles, 35 fourfolds, 21 fourfolds, seven sixfolds and one sevenfold)
Zawya
22-02-2025
- Business
- Zawya
Agthia unveils new products, seals strategic partnerships & wins sustainability award at Gulfood 2025
Awarded DNATA's 'Supplier of the Year 2025' for sustainable practices in rPET water supply. Commits to donating all remaining food items from Gulfood to local charities as part of the 'Year of Community' initiative. Dubai: Agthia Group, one of the region's leading food and beverage companies, marked its participation at the 30th edition of Gulfood 2025, held at Dubai World Trade Centre from February 17-21. With Agthia's expanding global reach, now spanning 67 markets across the Middle East, Asia, Europe, and the Americas, the Group showcased its diverse portfolio of over 35 brands, which continues to resonate with consumers seeking innovation and quality. As part of its ongoing commitment to product development, Agthia has also introduced two new variants under its Grand Mills brand: Patent Flour All Purpose, catering to a wide range of baking applications, and, Multigrain Atta, a nutritious blend of nine grains designed to support healthier lifestyles. Agthia also announced its partnership with Reliance Consumer Products to bring Campa Cola to the UAE, tapping into the strong nostalgia the brand holds for many, particularly the Indian expatriate community, while also appealing to local consumers. This collaboration enhances Agthia's diverse beverage portfolio and reinforces its market leadership in the region. Leveraging its extensive distribution network and industry expertise, Agthia aims to reintroduce Campa Cola to a new generation of consumers in the UAE. Agthia's industry leadership was further recognized with DNATA's 'Supplier of the Year 2025' award in the 'Most Sustainable Supplier' category. This accolade celebrates Agthia's contribution to Air Arabia through its supply of Al Ain rPET water bottles, showcasing the Group's commitment to integrating sustainability into its operations. Speaking about Agthia's participation at Gulfood 2025, Alan Smith Agthia's Chief Executive Officer, remarked: 'We see Gulfood as more than an industry event; it's a pulse check on the future of food. The F&B sector is undergoing a shift, shaped by changing consumer habits and new market realities. As an ambitious company, we embrace this evolution with a clear focus - building brands that stand the test of time, creating value through strategic partnerships, and ensuring our product portfolio continues to set new benchmarks in quality and experience. The future of food is being shaped today, and we are here to lead that conversation.' He also delivered a keynote address at the Gulfood CEO Summit, outlining the company's strategic direction in an increasingly dynamic F&B landscape. Highlighting the company's agility in responding to shifting consumer expectations, Smith reinforced Agthia's role in shaping the industry's future—leveraging its diverse portfolio, strategic partnerships, and market insights to deliver long-term value for consumers and stakeholders alike. In line with the UAE Government's declaration of 2025 as the 'Year of Community,' Agthia Group will donate all remaining food items from its Gulfood participation to local charities. This initiative reflects the Group's commitment to making a meaningful impact in the communities it serves. -Ends- About Agthia Agthia Group PJSC is a leading Abu Dhabi-based food and beverage company. Established in 2004, the Company is listed on the Abu Dhabi Securities Exchange (ADX) and has the symbol 'AGTHIA'. Agthia Group PJSC is part of ADQ, one of the region's largest holding companies with a broad portfolio of major enterprises spanning key sectors of Abu Dhabi's diversified economy. The Group's assets are located in the UAE, Saudi Arabia, Kuwait, Oman, Egypt, Turkey, and Jordan. Agthia offers a world-class portfolio of integrated businesses providing high-quality and trusted food and beverage products for consumers across the UAE, GCC, Turkey, the wider Middle East, South America and Asia. More than 12,000 employees are engaged in the manufacturing, distribution, and marketing of various products in categories such as Water & Food (Al Ain Water, Al Bayan, Alpin Natural Spring Water, VOSS, Al Ain Food & Trading Items); Snacking (Al Foah, Al Faysal Bakery & Sweets, BMB, Abu Auf); Protein and Frozen (Nabil Foods, Atyab, Al Ain Frozen Vegetables); and Agri-Business (Grand Mills, Agrivita). For more information, please visit or email us on corpcoms@ For media requests, please contact: Mohamed Rashaad - Media Relations Director, Influence Communications Email:
